Lipitor Sales Slowdown Reflects Overall Rx Market Trend, Pfizer Says
Executive Summary
A slowdown in the growth rate for Lipitor reflects the softness in overall prescription demand during the first quarter, Pfizer suggested during an April 22 earnings conference call
You may also be interested in...
Schering/Merck Ready For Vytorin; Lipid Market Growth Returns
Schering-Plough and Merck are likely to price the Zocor/Zetia combination Vytorin on par with Pfizer's Lipitor, Merck indicated during an April 22 conference call
Schering/Merck Ready For Vytorin; Lipid Market Growth Returns
Schering-Plough and Merck are likely to price the Zocor/Zetia combination Vytorin on par with Pfizer's Lipitor, Merck indicated during an April 22 conference call
Lipitor Scripts Rebounding, Pfizer Says; Cholesterol Category Still Has Life
Pfizer sees signs of a rebound in Lipitor (atorvastatin) prescriptions over the past six weeks, U.S. Pharmaceuticals President Pat Kelly said during Pfizer's June 17 analysts meeting in New York
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: